Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study

Mai Kimura, Yuichi Tamura, Makoto Takei, Tsunehisa Yamamoto, Tomohiko Ono, Jun Fujita, Masaharu Kataoka, Masataka Kuwana, Toru Satoh, Keiichi Fukuda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i (sildenafil and tadalafil at maximum dose). Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004) and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to 3.1 ± 0.8 L/min/m<sup>2</sup> (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively. Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.

Original languageEnglish
Article number62
JournalBMC Pulmonary Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 May 14

Fingerprint

Phosphodiesterase 5 Inhibitors
Pulmonary Hypertension
Therapeutics
Exercise Tolerance
Patient Rights
Cardiac Catheterization
Pharmaceutical Preparations
Vascular Resistance
Prostaglandins
Arterial Pressure
Hemodynamics
Safety
Lung

Keywords

  • New treatment option
  • Phosphodiesterase type 5 inhibitor
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension : A pilot study. / Kimura, Mai; Tamura, Yuichi; Takei, Makoto; Yamamoto, Tsunehisa; Ono, Tomohiko; Fujita, Jun; Kataoka, Masaharu; Kuwana, Masataka; Satoh, Toru; Fukuda, Keiichi.

In: BMC Pulmonary Medicine, Vol. 15, No. 1, 62, 14.05.2015.

Research output: Contribution to journalArticle

Kimura, Mai ; Tamura, Yuichi ; Takei, Makoto ; Yamamoto, Tsunehisa ; Ono, Tomohiko ; Fujita, Jun ; Kataoka, Masaharu ; Kuwana, Masataka ; Satoh, Toru ; Fukuda, Keiichi. / Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension : A pilot study. In: BMC Pulmonary Medicine. 2015 ; Vol. 15, No. 1.
@article{6204ca534cc2400eb69704e0eabbdd81,
title = "Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study",
abstract = "Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i (sildenafil and tadalafil at maximum dose). Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004) and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to 3.1 ± 0.8 L/min/m2 (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively. Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.",
keywords = "New treatment option, Phosphodiesterase type 5 inhibitor, Pulmonary arterial hypertension",
author = "Mai Kimura and Yuichi Tamura and Makoto Takei and Tsunehisa Yamamoto and Tomohiko Ono and Jun Fujita and Masaharu Kataoka and Masataka Kuwana and Toru Satoh and Keiichi Fukuda",
year = "2015",
month = "5",
day = "14",
doi = "10.1186/s12890-015-0037-8",
language = "English",
volume = "15",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension

T2 - A pilot study

AU - Kimura, Mai

AU - Tamura, Yuichi

AU - Takei, Makoto

AU - Yamamoto, Tsunehisa

AU - Ono, Tomohiko

AU - Fujita, Jun

AU - Kataoka, Masaharu

AU - Kuwana, Masataka

AU - Satoh, Toru

AU - Fukuda, Keiichi

PY - 2015/5/14

Y1 - 2015/5/14

N2 - Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i (sildenafil and tadalafil at maximum dose). Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004) and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to 3.1 ± 0.8 L/min/m2 (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively. Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.

AB - Background: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. Methods: We retrospectively analyzed 7 consecutive refractory patients with PAH administered either sildenafil 60 mg or tadalafil 40 mg as well as both ERA and prostanoid as combination therapies. All were started on the dual PDE5i (sildenafil and tadalafil at maximum dose). Results: Treatment was generally well tolerated without severe adverse events. On completion of the study, the seven patients received right heart catheterization and the 6-minute walk test (6WMT) 9.6 ± 1.4 months after initiation of the dual PDE5i therapy, showing significant improvements in hemodynamic parameters and exercise tolerance. Mean pulmonary arterial pressure and pulmonary vascular resistance decreased from 47.9 ± 9.7 to 41.7 ± 9.2 mmHg (P = 0.004) and 9.3 ± 2.7 to 6.7 ± 2.9 mmHg (P = 0.018), respectively. Cardiac index and 6MWT also increased from 2.8 ± 0.9 to 3.1 ± 0.8 L/min/m2 (P = 0.026) and 353 ± 60 to 382 ± 62 m (P = 0.014), respectively. Conclusion: The findings support dual PDE5i therapy as a new treatment option for refractory PAH.

KW - New treatment option

KW - Phosphodiesterase type 5 inhibitor

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84929332193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929332193&partnerID=8YFLogxK

U2 - 10.1186/s12890-015-0037-8

DO - 10.1186/s12890-015-0037-8

M3 - Article

C2 - 25971443

AN - SCOPUS:84929332193

VL - 15

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

IS - 1

M1 - 62

ER -